<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167817</url>
  </required_header>
  <id_info>
    <org_study_id>030762</org_study_id>
    <nct_id>NCT00167817</nct_id>
  </id_info>
  <brief_title>Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study</brief_title>
  <official_title>Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veterans Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veterans Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with schizophrenia are much more likely to be engaged in smoking and other addictive&#xD;
      behaviors, possibly related to biochemical abnormalities in the reward center of the brain.&#xD;
      The primary purpose of the present study is to investigate whether switching patients with&#xD;
      schizophrenia to a new atypical antipsychotic, aripiprazole, a drug with a novel mechanism of&#xD;
      action, will have an impact on smoking behavior.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an 8 week open label trial being conducted in stable adult outpatients with&#xD;
      schizophrenia who are smokers. The primary intervention is a switch in the subject's&#xD;
      antipsychotic to aripiprazole, flexibly dosed between 15-30 mg/day. The outcome measures&#xD;
      include a rating of smoking behavior using the Fagerstrom Test for Nicotine Dependence, and&#xD;
      saliva cotinine obtained at baseline and endpoint. Secondary measures include weight, serum&#xD;
      glucose and lipids, rating of symptom severity using the PANSS, and both ratings and&#xD;
      instrumental measures of motor functioning. We anticipate enrolling up to 25 subjects to&#xD;
      obtain the needed 15 completers at the week 8 endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saliva cotinine, Fagerstrom Test for Nicotine Dependence</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose and lipids</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of symptom severity using the PANSS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings and instrumental measures of motor functioning</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Schizophrenia, on stable antipsychotic dose for at least one month&#xD;
&#xD;
          2. Ages 18-65 inclusive&#xD;
&#xD;
          3. Overweight (body mass index of 25 kg/m2 or greater)&#xD;
&#xD;
          4. Daily cigarette smoker (by self-report)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Treatment refractory schizophrenia&#xD;
&#xD;
          3. Current treatment with clozapine&#xD;
&#xD;
          4. Current antipsychotic polypharmacy which may preclude monotherapy with aripiprazole&#xD;
&#xD;
          5. Documented poor compliance with oral antipsychotic medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan M Meyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>April 18, 2007</last_update_submitted>
  <last_update_submitted_qc>April 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2007</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>Smoking</keyword>
  <keyword>Metabolic</keyword>
  <keyword>Health</keyword>
  <keyword>Glucose</keyword>
  <keyword>Lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

